Oncology

The Malignant Pleural Mesothelioma Market includes several immunotherapy agents, in the pipeline including Keytruda, Opdivo and Yervoy, which have shown promising anticancer activity against mesothelioma in recent clinical trials. These drugs have been approved for other indications and now are being used in mono or combination therapy for mesothelioma. The most promising checkpoint inhibitors in mesothelioma research currently include Keytruda, Opdivo, Yervoy and Imfinzi (Durvalumab). Yervoy (ipilimumab for injection) is a recombinant, fully human monoclonal antibody that binds to and blocks human cytotoxic T lymphocyte-associated antigen 4 (CTLA-4). Opdivo is a...